Molecular Templates‘s patent involves cell-targeting molecules with Shiga toxin effector polypeptides, binding regions, and linker peptides for specific delivery to target cells. The molecules exhibit reduced immunogenicity and are suitable for therapeutic use in treating various diseases. GlobalData’s report on Molecular Templates gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Molecular Templates Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Molecular Templates, Peptide pharmacophores was a key innovation area identified from patents. Molecular Templates's grant share as of January 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.

Cell-targeting molecule with shiga toxin effector for therapy

Source: United States Patent and Trademark Office (USPTO). Credit: Molecular Templates Inc

A recently granted patent (Publication Number: US11857628B2) discloses a cell-targeting molecule designed for specific binding to extracellular target biomolecules. The molecule comprises a Shiga toxin effector polypeptide, a binding region for target biomolecules, and a linker peptide connecting the two regions. The Shiga toxin effector polypeptide includes specific amino acid sequences and substitutions, along with cysteines suitable for conjugation to other molecules. The binding region can include various amino acid residues suitable for conjugation to heterologous molecules, such as cysteine, lysine, histidine, or non-natural amino acid residues.

Furthermore, the patent claims cover a wide range of variations and applications for the cell-targeting molecule, including specific amino acid substitutions, linker peptide sequences, and binding region compositions. The molecule can be conjugated to various heterologous molecules, such as antibiotics, cytotoxic agents, radionuclides, or enzymes, for targeted therapeutic or diagnostic purposes. Additionally, the patent includes pharmaceutical compositions comprising the cell-targeting molecule and pharmaceutically acceptable excipients or carriers, highlighting the potential for developing novel targeted therapies based on this innovative technology.

To know more about GlobalData’s detailed insights on Molecular Templates, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies